Virologica Sinica

, Volume 23, Issue 6, pp 486–495

Prevention and treatment of KSHV-associated diseases with antiviral drugs


DOI: 10.1007/s12250-008-2995-y

Cite this article as:
Tian, R., Liao, Q. & Chen, X. Virol. Sin. (2008) 23: 486. doi:10.1007/s12250-008-2995-y


Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary, but not sufficient for the development of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). Advances in the prevention and treatment of KSHV-associated Diseases have been achieved, even though current treatment options are ineffective, or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required.

Key words

Antiviral drugs Kaposi’s sarcoma-associated herpesvirus (KSHV) Kaposi’s sarcoma (KS) Primary effusion lymphoma Multicentric castleman disease 

CLC number


Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag GmbH 2008

Authors and Affiliations

  1. 1.State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina

Personalised recommendations